# ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

> **NCT04904185** · PHASE1 · TERMINATED · sponsor: **Inge Marie Svane** · enrollment: 8 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **BIOLOGICAL:** Multiple Antigen Specific Endogenously derived T cells
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04904185
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-17
- **Primary completion:** 2024-06-07
- **Final completion:** 2024-06-07
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Evaluation of step A did not support addition of pembrolizumab in step B
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04904185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04904185, "ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04904185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*